317
Participants
Start Date
February 26, 2021
Primary Completion Date
May 16, 2023
Study Completion Date
May 16, 2023
CTP-543
Oral dosing
Placebo
Oral dosing
PEAK Research, LLC, Upper Saint Clair
Dermatology Associates of Plymouth Meeting, Plymouth Meeting
West End Dermatology Associates, Richmond
North Carolina Dermatology Associates, PLLC, Raleigh
Darst Dermatology, Charlotte
Dermatology Specialists of Charlotte, Charlotte
Clinical Research Center of the Carolinas, Charleston
Skin Care Research, LLC, Hollywood
Skin Care Research, LLC, Boca Raton
Total Skin and Beauty Dermatology Center, PC, Birmingham
DS Research, Louisville
Bexley Dermatology Research, Bexley
Remington Davis, Columbus
The Indiana Clinical Trials Center, PC, Plainfield
Michigan Center for Research Company, LLC, Clarkston
Minnesota Clinical Study Center, New Brighton
University of Minnesota Department of Dermatology, Minneapolis
DeNova Research, Chicago
Skin Specialists, PC, Omaha
Vital Prospects Clinical Research Institute, PC, Tulsa
Dermatology Treatment and Research Center, PA, Dallas
Austin Institute for Clinical Research, Houston
Austin Institute for Clinical Research, Inc., Pflugerville
Colorado Center for Dermatology and Skin Surgery, Centennial
Colorado Medical Research Center, Inc., Denver
Springville Dermatology/CCT Research, Springville
Center for Dermatology and Plastic Surgery/CCT Research, Scottsdale
Hope Clinical Research, Canoga Park
Quest Dermatology Research, Northridge
California Dermatology & Clinical Research Institute, Encinitas
Palmtree Clinical Research, Inc., Palm Springs
University of California, Irvine, Irvine
Kern Research, Inc., Bakersfield
Kaiser Permanente, San Francisco
Kaiser Permanente, Oakland
Northwest Dermatology, Portland
Yale University Church Street Research Unit, New Haven
Skin Laser and Surgery Specialists of New Jersey, Hackensack
Rhode Island Hospital, Providence
Lead Sponsor
Concert Pharmaceuticals
INDUSTRY